Live Analyst Rating Changes 23588 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/William Plovanic
CG

William Plovanic

Canaccord Genuity
Wall Street Analyst
★★★★☆
#507
on 13Foresight · ranked by our own returns
65%
Success Rate
+11.8%
Average Return
42 of 65 calls profitable · +2.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 65% of William Plovanic's ratings turned a profit when each position was held for 1 year — averaging +11.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

135 Buy 12 Hold 0 Sell
William's Stock Coverage 37 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
PLSE
Pulse Biosciences
 Aug 10, 2026 BUY Strong Buy
-4.7% avg upside
5 analysts
$43.00
3.61% Upside
 +4.4% ·
CVRX
CVRx
 Aug 07, 2026 BUY Buy
+190.5% avg upside
9 analysts
$5.00
111.00% Upside
 +0.0% ·
TLSI
TriSalus Life Sciences
 Aug 07, 2026 BUY Strong Buy
+71.3% avg upside
8 analysts
$7.00
25.48% Upside
 +0.0% ·
AORT
Artivion
 Aug 07, 2026 BUY Strong Buy
+48.6% avg upside
8 analysts
$39.00
48.24% Upside
 +0.0% ·
IRTC
Irhythm Technologies
 Aug 07, 2026 BUY Strong Buy
+28.9% avg upside
20 analysts
$196.00
56.98% Upside
 -4.8% ·
TNDM
Tandem Diabetes Care
 Aug 07, 2026 BUY Buy
+39.8% avg upside
29 analysts
$40.00
75.28% Upside
 +2.4% ·
PODD
Insulet
 Aug 06, 2026 BUY Strong Buy
+50.6% avg upside
32 analysts
$179.00
25.21% Upside
 +4.1% ·
ATEC
Alphatec Holdings
 Aug 05, 2026 BUY Strong Buy
+77.3% avg upside
23 analysts
$19.00
100.24% Upside
 -2.0% ·
TMDX
TransMedics Group
 Aug 05, 2026 BUY Strong Buy
+16.6% avg upside
15 analysts
$95.00
7.46% Upside
 +13.5% ·
PEN
Penumbra
 Aug 04, 2026 HOLD Buy
+1.2% avg upside
23 analysts
$374.00
14.67% Upside
 +0.7% ·
EW
Edwards Lifesciences
 Aug 03, 2026 HOLD Strong Buy
+7.8% avg upside
34 analysts
$85.00
7.64% Downside
 +5.0% ·
CBLL
Ceribell, Inc.
 Aug 03, 2026 BUY Strong Buy
+20.7% avg upside
8 analysts
$25.00
29.50% Upside
 +19.1% ·
DXCM
Dexcom
 Aug 03, 2026 BUY Strong Buy
+19.0% avg upside
32 analysts
$90.00
2.74% Upside
 +2.4% ·
BSX
Boston Scientific
 Jul 30, 2026 BUY Strong Buy
+32.8% avg upside
38 analysts
$66.00
30.89% Upside
 +11.8% ·
ATRC
Atricure
 Jul 23, 2026 BUY Strong Buy
+8.1% avg upside
13 analysts
$55.00
31.99% Upside
 +30.3% ·
HTFL
HeartFlow, Inc.
 Jun 29, 2026 BUY Strong Buy
+23.4% avg upside
9 analysts
$37.00
26.15% Upside
 -16.6% ·
STIM
Neuronetics
 Apr 06, 2026 BUY Strong Buy
+118.9% avg upside
7 analysts
$3.00
38.32% Upside
 +35.2% ·
GMED
Globus Medical
 Jan 22, 2024 BUY Strong Buy
+7.9% avg upside
24 analysts
$79.00
8.33% Downside
 +66.5% ·
SIBN
SI-Bone
 Jan 22, 2024 BUY Strong Buy
+37.7% avg upside
18 analysts
$25.00
32.76% Upside
 -13.8% ·
AXGN
AxoGen
 Dec 21, 2023 BUY Strong Buy
-27.4% avg upside
21 analysts
$15.00
68.90% Downside
 +118.7% ·
ANGO
AngioDynamics
 Dec 21, 2023 BUY Strong Buy
+12.4% avg upside
9 analysts
$19.00
20.67% Upside
 +14.4% ·
ZBH
Zimmer Biomet Holdings
 Dec 15, 2023 HOLD Buy
+17.5% avg upside
38 analysts
$131.00
34.04% Upside
 -9.3% ·
SYK
Stryker
 Dec 15, 2023 HOLD Strong Buy
+6.1% avg upside
37 analysts
$300.00
13.26% Downside
 +30.3% ·
BVS
Bioventus
 Dec 07, 2023 BUY Strong Buy
-2.9% avg upside
8 analysts
$7.00
49.91% Downside
 +128.6% ·
SNN
Smith & Nephew Snats
 Nov 30, 2023 HOLD Buy
+12.0% avg upside
14 analysts
$32.00
6.44% Upside
 +2.2% ·
ENOV
Enovis
 Nov 07, 2023 BUY Strong Buy
+172.7% avg upside
39 analysts
$65.00
168.09% Upside
 -1.0% ·
STAA
Staar Surgical
 Sep 15, 2023 HOLD Hold
+35.4% avg upside
16 analysts
$43.00
71.12% Upside
 -25.3% ·
MMSI
Merit Medical Systems
 Aug 28, 2023 HOLD Strong Buy
+8.9% avg upside
15 analysts
$70.00
22.07% Downside
 +45.4% ·
AFIB
Acutus Medical
 Aug 08, 2023 HOLD Sell
+494900.1% avg upside
5 analysts
$0.74
739900.09% Upside
 · ·
LUNG
Pulmonx
 Feb 23, 2023 BUY Buy
+216.3% avg upside
9 analysts
$20.00
777.18% Upside
 +2.7% ·
OCGN
Ocugen
 Feb 02, 2016 BUY Strong Buy
+584.3% avg upside
17 analysts
$8.00
510.66% Upside
 · ·
MDXG
MiMedx Group
 Jan 11, 2016 BUY Strong Buy
+148.5% avg upside
17 analysts
$12.00
181.08% Upside
 +1.5% ·
LFWD
Lifeward
 Nov 05, 2015 BUY Strong Buy
-4.5% avg upside
8 analysts
$16.00
107.60% Upside
 · ·
GADS
Gadsden Prop
 Feb 02, 2015 HOLD Buy
+3599900.1% avg upside
5 analysts
 — · ·
LIVN
LivaNova
 Jun 05, 2014 BUY Strong Buy
+4.4% avg upside
15 analysts
$63.00
17.67% Downside
 · ·
OFIX
Orthofix Medical
 Sep 09, 2011 BUY Buy
+174.3% avg upside
15 analysts
$45.00
338.62% Upside
 +27.7% ·
IART
Integra Lifesciences
 Jun 28, 2011 BUY Buy
+150.1% avg upside
21 analysts
 — -23.8% ·
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
William Plovanic — Frequently Asked Questions
How accurate are William Plovanic's stock ratings?
Based on the calls 13Foresight could measure, about 65% of William's ratings were profitable over a one-year hold, with an average return of +11.8% per rating, or +2.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is William ranked on 13Foresight?
William Plovanic is currently ranked #507 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does William cover?
William most recently has ratings on PLSE, CVRX, TLSI, AORT, IRTC, TNDM, PODD, ATEC, TMDX, PEN, EW, CBLL and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.